Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Medicine

Topics

Medicine

Cancer Oncology

Internal Medicine

Gastroenterology

Hepatology

Show all topics

DOI

10.1097/md.0000000000039289

License

CC-BY-NC